SAA1 and metabolic dysfunction-associated steatotic liver disease: Jiang et al. demonstrated that SAA1 was increased in the NAFLD liver in both humans and mice, and SAA1/1 deficiency alleviated HFD‐induced metabolic disorder, hepatic steatosis and inflammation.